NOT AVAILABLE IN THE U.S.A.
The Welch Allyn RETeval-DR Electroretinograph is designed for healthcare providers who want to improve management of their patients with diabetes. In just three minutes, you can objectively screen for vision-threatening diabetic retinopathy (VTDR) wherever patients receive care. Welch Allyn RETeval-DR Electroretinograph enables efficient, comfortable, non-mydriatic screening for VTDR that improves patient compliance to help preserve vision in your patients with diabetes.
RETeval-DR can safely identify patients at low risk for blindness from diabatic retinopathy with 99.2% negative predictive value*, thereby allowing eye care providers to focus more time on patients with vision-threatening diabetic retinopathy.
The Welch Allyn Vision For All initiative is focused on delivering frontline solutions that will help to reduce or eliminate some of the leading causes of preventable blindness and vision-threatening conditions. This effort is dedicated to improving patient access to vision-saving technology by providing simple, affordable, advanced screening solutions to primary care physicians and eye care specialists.
Thank you for your interest in the Welch Allyn RETeval-DR Electroretinograph. A representative will contact you shortly.